GTX (NASDAQ:GTXI) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.05, Bloomberg Earnings reports.
GTX (NASDAQ GTXI) opened at $20.25 on Wednesday. GTX has a fifty-two week low of $2.73 and a fifty-two week high of $23.40.
Several brokerages recently weighed in on GTXI. BidaskClub lowered GTX from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 14th. Robert W. Baird began coverage on GTX in a report on Tuesday, November 21st. They issued an “outperform” rating and a $17.00 price objective for the company. ValuEngine raised GTX from a “sell” rating to a “hold” rating in a report on Wednesday, February 7th. Stifel Nicolaus upped their target price on GTX from $16.00 to $45.00 and gave the company a “buy” rating in a report on Monday, March 5th. Finally, Zacks Investment Research raised GTX from a “sell” rating to a “hold” rating in a report on Wednesday, January 17th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $32.50.
In other news, CEO Marc Steven Hanover sold 7,309 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $11.33, for a total transaction of $82,810.97. Following the completion of the transaction, the chief executive officer now directly owns 129,990 shares of the company’s stock, valued at $1,472,786.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jason T. Shackelford sold 3,090 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $11.33, for a total value of $35,009.70. Following the transaction, the insider now directly owns 31,111 shares of the company’s stock, valued at $352,487.63. The disclosure for this sale can be found here. Insiders have sold 15,364 shares of company stock valued at $174,074 over the last ninety days. Corporate insiders own 41.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “GTX (GTXI) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://ledgergazette.com/2018/03/14/gtx-gtxi-announces-quarterly-earnings-results-beats-expectations-by-0-05-eps.html.
GTX Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.